Please note that nominations for 2025 are now closed.
This Lectureship celebrates outstanding early career researchers, in academia or industry, who have made significant contributions in the fields of medicinal chemistry and drug discovery in their independent careers.
- It is presented annually
- The nominations are shortlisted, and the winner is selected by a judging panel made up of the RSC Medicinal 91AV Editorial Board
- The recipient of this lectureship receives the opportunity to present at a relevant high-profile international meeting with a contribution of up to £1,000 to cover associated costs
Our latest winner 2025
Professor Michael Bollong
Michael earned his BS in biochemistry and cell biology from the University of California, San Diego (2009) and his PhD in chemistry from Scripps Research (2016) under the mentorship of Pete Schultz. He was the inaugural Scripps Fellow (2017), an early independence principal investigator position.
In 2020, he became an Assistant Professor in the Department of 91AV at Scripps Research and is currently the Early Career Endowed Roon Chair for Cardiovascular Research as an Associate Professor. His laboratory uses chemical genetics as a discovery paradigm, focusing on the identification and development of drug-like small molecules with novel biological functions. One key focus of his laboratory has been identifying molecules which promote reparative organ regeneration, a largely unmet challenge in the field of regenerative medicine.
See all our previous winners
Guidelines for nominators and candidates
Find out who is eligible for this lectureship, about the nomination process and see who is on the selection panel.
Nomination deadline
Closed for 2025
Lectureship announcement deadline
See our latest winner above
The RSC Medicinal 91AV Lectureship is awarded through a process whereby nominations of candidates are invited from our community.
Open to all researchers globally
This Lectureship is open to all researchers throughout the world. This includes, but is not limited to, members of the 91AV and researchers in academia or industry.
We believe we have a responsibility to promote inclusivity and accessibility to improve diversity. Where possible, we encourage each nominator to consider nominating candidates of all genders, races, and backgrounds. Please see our approach to Inclusion and Diversity.
Eligibility
To be eligible for the RSC Medicinal 91AV Lectureship, the candidate must:
- Be an active medicinal chemistry researcher, either in academia or industry, carrying out research that is within the scope of the journal
- Be an independent researcher (this includes team leaders in industry and Research Associates or Fellows who run their own research group; PhD students and postdocs are not eligible)
- Be at an early stage of their independent career (this should typically be within 12 years of completing their PhD, but appropriate consideration will be given to those who have taken a career break, followed a different career path or work in systems where their time period to independence may vary). Please contact the Editorial Office if you have any queries
When nominations are open:
Nominations can be made by anyone and must be sent via email to the Editorial Office. Self-nominations are not permitted. All nominators will be asked to confirm that, to the best of their knowledge, their nominee’s professional standing is such that there is no confirmed or potential impediment to them receiving the Lectureship.
To nominate a candidate, please provide:
- The name, affiliation, website URL and contact details of the nominee
- An up-to-date nominee CV (3 page maximum)
- A letter of recommendation (500-word limit). Statements as to why a nominee is eligible if they are beyond 12 years of their PhD completion, for instance, due to career breaks, will not count towards this word limit
- Contact details for a confirmed supporting referee. Please inform your referee of the nomination that the Editorial Office will request a supporting letter of recommendation (500-word limit) from them once the nomination has been received, where the referee should comment in detail on specific contributions, achievements and potential. Referees must state their relationship with the nominee e.g. this could be the nominee’s postdoc or PhD supervisor, line manager, project manager or academic mentor
All eligible nominated candidates will be assessed by a judging panel made up of the RSC Medicinal 91AV Editorial Board. Any Editorial Board members who have a conflict of interest will be removed from the selection panel.
The judging panel will consider the following core criteria:
- excellence in research, as evidenced with reference to originality and impact
- quality of publications/patents/software
- innovation
- collaborations and teamwork
- community and advocacy activities
Additional indicators of esteem will be considered by the judging panel where multiple nominees are judged equally meritorious in relation to these core criteria.
Previous winners
Current winner: , Scripps Research, USA
2024: , Technical University of Denmark, Denmark
2023: , Australian National University, Australia
2022: , Weizmann Institute of Science, Israel
2021: , GSK and the Francis Crick Institute, UK
2020: , Max Planck Institute of Colloids and Interfaces, Germany
2019: , Duke University, USA
2018: , University of Cambridge, UK
2017: , Leiden University, Netherlands
2016: , University of Dundee, UK
2015: , University of Sydney, Australia
2014: , University of Toronto, Canada
2013: , École Polytechnique Fédérale de Lausanne, Switzerland
See all our lectureships
Contact RSC Medicinal 91AV Editorial Office
- Email:
- the team